The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation

Cyclophosphamide followed by Intravenous Targeted Busulfan for Allogeneic Hematopoietic Cell Transplantation: Pharmacokinetics and Clinical Outcomes

(2013) Andrew R. Rezvani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients

(2013) M Ansari et al.   BONE MARROW TRANSPLANTATION

Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation

(2013) In-Wha Kim et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT

(2012) P Balasubramanian et al.   BONE MARROW TRANSPLANTATION

Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

(2012) Suvi T. M. Orr et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

(2012) Moustapha Hassan et al.   PHARMACOGENOMICS

A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry

(2012) Marc Ansari et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Busulfan and Metronidazole: An Often Forgotten but Significant Drug Interaction

(2011) Alison M Gulbis et al.   ANNALS OF PHARMACOTHERAPY

Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT

(2011) M H ten Brink et al.   BONE MARROW TRANSPLANTATION

Reversible and irreversible protein glutathionylation: biological and clinical aspects

(2011) Arthur JL Cooper et al.   Expert Opinion on Drug Metabolism & Toxicology

Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients

(2011) John L. Black et al.   LEUKEMIA RESEARCH

Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis

(2011) Evan J Begg et al.   PHARMACOGENOMICS

Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation

(2010) Stacy E.F. Melanson et al.   AMERICAN JOURNAL OF HEMATOLOGY

Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT

(2010) N Cantoni et al.   BONE MARROW TRANSPLANTATION

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation

(2010) Nuala A. Helsby et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations

(2010) Rasmus S. Pedersen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Influence of GST gene polymorphisms on busulfan pharmacokinetics in children

(2009) M Ansari et al.   BONE MARROW TRANSPLANTATION

Can the pharmacogenetics ofGSTgene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?

(2009) Marc Ansari et al.   PHARMACOGENOMICS

Metabolism of the Cysteine S-Conjugate of Busulfan Involves a  -Lyase Reaction

(2008) A. J. L. Cooper et al.   DRUG METABOLISM AND DISPOSITION

Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia

(2008) V Rocha et al.   LEUKEMIA